Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

Authors:
Nadeem R. Abu-Rustum Memorial Sloan Kettering Cancer Center

Search for other papers by Nadeem R. Abu-Rustum in
Current site
Google Scholar
PubMed
Close
 MD
,
Catheryn M. Yashar UC San Diego Moores Cancer Center

Search for other papers by Catheryn M. Yashar in
Current site
Google Scholar
PubMed
Close
 MD
,
Rebecca Arend O’Neal Comprehensive Cancer Center at UAB

Search for other papers by Rebecca Arend in
Current site
Google Scholar
PubMed
Close
 MD
,
Emma Barber Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Search for other papers by Emma Barber in
Current site
Google Scholar
PubMed
Close
 MD
,
Kristin Bradley University of Wisconsin Carbone Cancer Center

Search for other papers by Kristin Bradley in
Current site
Google Scholar
PubMed
Close
 MD
,
Rebecca Brooks UC Davis Comprehensive Cancer Center

Search for other papers by Rebecca Brooks in
Current site
Google Scholar
PubMed
Close
 MD
,
Susana M. Campos Dana-Farber/Brigham and Women’s Cancer Center

Search for other papers by Susana M. Campos in
Current site
Google Scholar
PubMed
Close
 MD, MPH, MS
,
Junzo Chino Duke Cancer Institute

Search for other papers by Junzo Chino in
Current site
Google Scholar
PubMed
Close
 MD
,
Hye Sook Chon Moffitt Cancer Center

Search for other papers by Hye Sook Chon in
Current site
Google Scholar
PubMed
Close
 MD
,
Marta Ann Crispens Vanderbilt-Ingram Cancer Center

Search for other papers by Marta Ann Crispens in
Current site
Google Scholar
PubMed
Close
 MD
,
Shari Damast Yale Cancer Center/Smilow Cancer Hospital

Search for other papers by Shari Damast in
Current site
Google Scholar
PubMed
Close
 MD
,
Christine M. Fisher University of Colorado Cancer Center

Search for other papers by Christine M. Fisher in
Current site
Google Scholar
PubMed
Close
 MD, MPH
,
Peter Frederick Roswell Park Comprehensive Cancer Center

Search for other papers by Peter Frederick in
Current site
Google Scholar
PubMed
Close
 MD
,
David K. Gaffney Huntsman Cancer Institute at the University of Utah

Search for other papers by David K. Gaffney in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Stephanie Gaillard The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Search for other papers by Stephanie Gaillard in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Robert Giuntoli II Abramson Cancer Center at the University of Pennsylvania

Search for other papers by Robert Giuntoli II in
Current site
Google Scholar
PubMed
Close
 MD
,
Scott Glaser City of Hope National Medical Center

Search for other papers by Scott Glaser in
Current site
Google Scholar
PubMed
Close
 MD
,
Jordan Holmes Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Search for other papers by Jordan Holmes in
Current site
Google Scholar
PubMed
Close
 MD, MPH
,
Brooke E. Howitt Stanford Cancer Institute

Search for other papers by Brooke E. Howitt in
Current site
Google Scholar
PubMed
Close
 MD
,
Kari Kendra The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Search for other papers by Kari Kendra in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Jayanthi Lea UT Southwestern Simmons Comprehensive Cancer Center

Search for other papers by Jayanthi Lea in
Current site
Google Scholar
PubMed
Close
 MD
,
Nita Lee The UChicago Medicine Comprehensive Cancer Center

Search for other papers by Nita Lee in
Current site
Google Scholar
PubMed
Close
 MD
,
Gina Mantia-Smaldone Fox Chase Cancer Center

Search for other papers by Gina Mantia-Smaldone in
Current site
Google Scholar
PubMed
Close
 MD
,
Andrea Mariani Mayo Clinic Comprehensive Cancer Center

Search for other papers by Andrea Mariani in
Current site
Google Scholar
PubMed
Close
 MD
,
David Mutch Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Search for other papers by David Mutch in
Current site
Google Scholar
PubMed
Close
 MD
,
Christa Nagel The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Search for other papers by Christa Nagel in
Current site
Google Scholar
PubMed
Close
 MD
,
Larissa Nekhlyudov Dana-Farber/Brigham and Women’s Cancer Center

Search for other papers by Larissa Nekhlyudov in
Current site
Google Scholar
PubMed
Close
 MD, MPH
,
Mirna Podoll Vanderbilt-Ingram Cancer Center

Search for other papers by Mirna Podoll in
Current site
Google Scholar
PubMed
Close
 MD
,
Kerry Rodabaugh Fred & Pamela Buffett Cancer Center

Search for other papers by Kerry Rodabaugh in
Current site
Google Scholar
PubMed
Close
 MD
,
Ritu Salani UCLA Jonsson Comprehensive Cancer Center

Search for other papers by Ritu Salani in
Current site
Google Scholar
PubMed
Close
 MD, MBA
,
John Schorge St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center

Search for other papers by John Schorge in
Current site
Google Scholar
PubMed
Close
 MD
,
Jean Siedel University of Michigan Rogel Cancer Center

Search for other papers by Jean Siedel in
Current site
Google Scholar
PubMed
Close
 DO, MS
,
Rachel Sisodia Mass General Cancer Center

Search for other papers by Rachel Sisodia in
Current site
Google Scholar
PubMed
Close
 MD
,
Pamela Soliman The University of Texas MD Anderson Cancer Center

Search for other papers by Pamela Soliman in
Current site
Google Scholar
PubMed
Close
 MD, MPH
,
Stefanie Ueda UCSF Helen Diller Family Comprehensive Cancer Center

Search for other papers by Stefanie Ueda in
Current site
Google Scholar
PubMed
Close
 MD
,
Renata Urban Fred Hutchinson Cancer Center

Search for other papers by Renata Urban in
Current site
Google Scholar
PubMed
Close
 MD
,
Stephanie L. Wethington The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Search for other papers by Stephanie L. Wethington in
Current site
Google Scholar
PubMed
Close
 MD, MSc
,
Emily Wyse Patient Advocate

Search for other papers by Emily Wyse in
Current site
Google Scholar
PubMed
Close
,
Kristine Zanotti Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Search for other papers by Kristine Zanotti in
Current site
Google Scholar
PubMed
Close
 MD
,
Nicole McMillian National Comprehensive Cancer Network

Search for other papers by Nicole McMillian in
Current site
Google Scholar
PubMed
Close
 MS
, and
Sara Espinosa National Comprehensive Cancer Network

Search for other papers by Sara Espinosa in
Current site
Google Scholar
PubMed
Close
 PhD
Restricted access

Vulvar cancer is annually diagnosed in an estimated 6,470 individuals and the vast majority are histologically squamous cell carcinomas. Vulvar cancer accounts for 5% to 8% of gynecologic malignancies. Known risk factors for vulvar cancer include increasing age, infection with human papillomavirus, cigarette smoking, inflammatory conditions affecting the vulva, and immunodeficiency. Most vulvar neoplasias are diagnosed at early stages. Rarer histologies exist and include melanoma, extramammary Paget’s disease, Bartholin gland adenocarcinoma, verrucous carcinoma, basal cell carcinoma, and sarcoma. This manuscript discusses recommendations outlined in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for treatments, surveillance, systemic therapy options, and gynecologic survivorship.

Individual Disclosures for the NCCN Vulvar Cancer Panel
Individual Disclosures for the NCCN Vulvar Cancer Panel

  • Collapse
  • Expand
  • 1.

    Farias-Eisner R, Cirisano FD, Grouse D, et al. Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2N0-1M0) disease. Gynecol Oncol 1994;53:5558.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Ansink A, van der Velden J. Surgical interventions for early squamous cell carcinoma of the vulva. Cochrane Database Syst Rev 2000;2000:CD002036.

  • 3.

    Hacker NF, Berek JS, Lagasse LD, et al. Individualization of treatment for stage I squamous cell vulvar carcinoma. Obstet Gynecol 1984;63:155162.

  • 4.

    Burke TW, Levenback C, Coleman RL, et al. Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol 1995;57:215220.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Hacker NF, van der Velden J. Conservative management of early vulvar cancer. Cancer 1993;71(4 Suppl):16731677.

  • 6.

    Morgan MA, Mikuta JJ. Surgical management of vulvar cancer. Semin Surg Oncol 1999;17:168172.

  • 7.

    de Hullu JA, Hollema H, Lolkema S, et al. Vulvar carcinoma. The price of less radical surgery. Cancer 2002;95:23312338.

  • 8.

    Heaps JM, Fu YS, Montz FJ, et al. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 1990;38:309314.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Rouzier R, Haddad B, Plantier F, et al. Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet Gynecol 2002;100:11591167.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Chan JK, Sugiyama V, Pham H, et al. Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol 2007;104:636641.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    DeSimone CP, Van Ness JS, Cooper AL, et al. The treatment of lateral T1 and T2 squamous cell carcinomas of the vulva confined to the labium majus or minus. Gynecol Oncol 2007;104:390395.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    van der Velden J, Fons G, Lawrie TA. Primary groin irradiation versus primary groin surgery for early vulvar cancer. Cochrane Database Syst Rev 2011;2011:CD002224.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Stehman FB, Bundy BN, Thomas G, et al. Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1992;24:389396.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Hallak S, Ladi L, Sorbe B. Prophylactic inguinal-femoral irradiation as an alternative to primary lymphadenectomy in treatment of vulvar carcinoma. Int J Oncol 2007;31:10771085.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Petereit DG, Mehta MP, Buchler DA, et al. Inguinofemoral radiation of N0,N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. Int J Radiat Oncol Biol Phys 1993;27:963967.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Rouzier R, Haddad B, Atallah D, et al. Surgery for vulvar cancer. Clin Obstet Gynecol 2005;48:869878.

  • 17.

    Stehman FB, Look KY. Carcinoma of the vulva. Obstet Gynecol 2006;107:719733.

  • 18.

    Magrina JF, Gonzalez-Bosquet J, Weaver AL, et al. Squamous cell carcinoma of the vulva stage IA: long-term results. Gynecol Oncol 2000;76:2427.

  • 19.

    Yoder BJ, Rufforny I, Massoll NA, et al. Stage IA vulvar squamous cell carcinoma: an analysis of tumor invasive characteristics and risk. Am J Surg Pathol 2008;32:765772.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Wilkinson EJ. Superficial invasive carcinoma of the vulva. Clin Obstet Gynecol 1985;28:188195.

  • 21.

    Coleman RL, Ali S, Levenback CF, et al. Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Gynecol Oncol 2013;128:155159.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Woelber L, Eulenburg C, Grimm D, et al. The risk of contralateral non-sentinel metastasis in patients with primary vulvar cancer and unilaterally positive sentinel node. Ann Surg Oncol 2016;23:25082514.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Van der Kolk WL, Van der Zee AG, Slomovitz BM, et al. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe. Gynecol Oncol 2022;167:310.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Greer BE, Berek JS, eds. Current Topics In Obstetrics And Gynecology: Gynecologic Oncology: Treatment Rationale And Techniques. Elsevier; 1991.

    • PubMed
    • Export Citation
  • 25.

    Forner DM, Lampe B. Exenteration in the treatment of stage III/IV vulvar cancer. Gynecol Oncol 2012;124:8791.

  • 26.

    Miller B, Morris M, Levenback C, et al. Pelvic exenteration for primary and recurrent vulvar cancer. Gynecol Oncol 1995;58:202205.

  • 27.

    Hoffman MS, Cavanagh D, Roberts WS, et al. Ultraradical surgery for advanced carcinoma of the vulva: an update. Int J Gynecol Cancer 1993;3:369372.

  • 28.

    Gadducci A, Cionini L, Romanini A, et al. Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol 2006;60:227241.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Boronow RC. Combined therapy as an alternative to exenteration for locally advanced vulvo-vaginal cancer: rationale and results. Cancer 1982;49:10851091.

  • 30.

    Fuh KC, Berek JS. Current management of vulvar cancer. Hematol Oncol Clin North Am 2012;26:4562.

  • 31.

    Leiserowitz GS, Russell AH, Kinney WK, et al. Prophylactic chemoradiation of inguinofemoral lymph nodes in patients with locally extensive vulvar cancer. Gynecol Oncol 1997;66:509514.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Russell AH, Mesic JB, Scudder SA, et al. Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva. Gynecol Oncol 1992;47:1420.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Thomas G, Dembo A, DePetrillo A, et al. Concurrent radiation and chemotherapy in vulvar carcinoma. Gynecol Oncol 1989;34:263267.

  • 34.

    Eifel PJ, Morris M, Burke TW, et al. Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Gynecol Oncol 1995;59:5156.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Lupi G, Raspagliesi F, Zucali R, et al. Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. Cancer 1996;77:14721478.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Moore DH, Thomas GM, Montana GS, et al. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:7985.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Geisler JP, Manahan KJ, Buller RE. Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. Gynecol Oncol 2006;100:5357.

  • 38.

    Landoni F, Maneo A, Zanetta G, et al. Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. Gynecol Oncol 1996;61:321327.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Berek JS, Heaps JM, Fu YS, et al. Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Gynecol Oncol 1991;42:197201.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Koh WJ, Wallace HJ 3rd, Greer BE, et al. Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer. Int J Radiat Oncol Biol Phys 1993;26:809816.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Cunningham MJ, Goyer RP, Gibbons SK, et al. Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva. Gynecol Oncol 1997;66:258261.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Gerszten K, Selvaraj RN, Kelley J, et al. Preoperative chemoradiation for locally advanced carcinoma of the vulva. Gynecol Oncol 2005;99:640644.

  • 43.

    Tans L, Ansink AC, van Rooij PH, et al. The role of chemo-radiotherapy in the management of locally advanced carcinoma of the vulva: single institutional experience and review of literature. Am J Clin Oncol 2011;34:2226.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Han SC, Kim DH, Higgins SA, et al. Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva. Int J Radiat Oncol Biol Phys 2000;47:12351244.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Rao YJ, Chin RI, Hui C, et al. Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: a review of the National Cancer Database. Gynecol Oncol 2017;146:572579.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Montana GS, Thomas GM, Moore DH, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2000;48:10071013.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Moore DH, Ali S, Koh WJ, et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol 2012;124:529533.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    van Triest B, Rasing M, van der Velden J, et al. Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: an efficacy study. Gynecol Oncol 2021;163:117124.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Natesan D, Hong JC, Foote J, et al. Primary versus preoperative radiation for locally advanced vulvar cancer. Int J Gynecol Cancer 2017;27:794804.

  • 50.

    Shylasree TS, Bryant A, Howells RE. Chemoradiation for advanced primary vulval cancer. Cochrane Database Syst Rev 2011;2011:CD003752.

  • 51.

    van Doorn HC, Ansink A, Verhaar-Langereis M, et al. Neoadjuvant chemoradiation for advanced primary vulvar cancer. Cochrane Database Syst Rev 2006;2006:CD003752.

  • 52.

    Reade CJ, Eiriksson LR, Mackay H. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecol Oncol 2014;132:780789.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Candelaria M, Garcia-Arias A, Cetina L, et al. Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol 2006;1:15.

  • 54.

    Lorvidhaya V, Chitapanarux I, Sangruchi S, et al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 2003;55:12261232.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Cerrotta A, Gardan G, Cavina R, et al. Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose. Eur J Gynaecol Oncol 2002;23:115119.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Pattaranutaporn P, Thirapakawong C, Chansilpa Y, et al. Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. Gynecol Oncol 2001;81:404407.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Han SN, Vergote I, Amant F. Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer. Int J Gynecol Cancer 2012;22:865868.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Witteveen PO, van der Velden J, Vergote I, et al. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer—Gynaecological Cancer Group). Ann Oncol 2009;20:15111516.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Horowitz NS, Olawaiye AB, Borger DR, et al. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol 2012;127:141146.

  • 60.

    Jolly S, Soni P, Gaffney DK, et al. ACR Appropriateness Criteria adjuvant therapy in vulvar cancer. Oncology (Williston Park) 2015;29:867872; 874865.

  • 61.

    Homesley HD, Bundy BN, Sedlis A, et al. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol 1986;68:733740.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Kunos C, Simpkins F, Gibbons H, et al. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstet Gynecol 2009;114:537546.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Swanick CW, Eifel PJ, Huo J, et al. Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with node-positive vulvar cancer. Gynecol Oncol 2017;146:8793.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Fons G, Groenen SM, Oonk MH, et al. Adjuvant radiotherapy in patients with vulvar cancer and one intra capsular lymph node metastasis is not beneficial. Gynecol Oncol 2009;114:343345.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Mahner S, Jueckstock J, Hilpert F, et al. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst 2015;107:dju426.

  • 66.

    Parthasarathy A, Cheung MK, Osann K, et al. The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecol Oncol 2006;103:10951099.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Woelber L, Eulenburg C, Choschzick M, et al. Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment. Int J Gynecol Cancer 2012;22:503508.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Gill BS, Bernard ME, Lin JF, et al. Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: a National Cancer Data Base (NCDB) analysis. Gynecol Oncol 2015;137:365372.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Swanick CW, Smith GL, Huo J, et al. Delivery and outcomes of adjuvant radiation therapy in older women with node-positive vulvar cancer. Oncology (Williston Park) 2016;30(Suppl 1):Abstract P021.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Ignatov T, Eggemann H, Burger E, et al. Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins. J Cancer Res Clin Oncol 2016;142:489495.

  • 71.

    Viswanathan AN, Pinto AP, Schultz D, et al. Relationship of margin status and radiation dose to recurrence in post-operative vulvar carcinoma. Gynecol Oncol 2013;130:545549.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 2008;26:884889.

  • 73.

    van Beekhuizen HJ, Auzin M, van den Einden LC, et al. Lymph node count at inguinofemoral lymphadenectomy and groin recurrences in vulvar cancer. Int J Gynecol Cancer 2014;24:773778.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Bell JG, Lea JS, Reid GC. Complete groin lymphadenectomy with preservation of the fascia lata in the treatment of vulvar carcinoma. Gynecol Oncol 2000;77:314318.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Stehman FB, Bundy BN, Dvoretsky PM, et al. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol 1992;79:490497.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Kirby TO, Rocconi RP, Numnum TM, et al. Outcomes of stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy. Gynecol Oncol 2005;98:309312.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Gonzalez Bosquet J, Magrina JF, Gaffey TA, et al. Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. Gynecol Oncol 2005;97:828833.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Nooij LS, van den Brand FA, Gaarenstroom KN, et al. Risk factors and treatment for recurrent vulvar squamous cell carcinoma. Crit Rev Oncol Hematol 2016;106:113.

  • 79.

    Gien LT, Sutradhar R, Thomas G, et al. Patient, tumor, and health system factors affecting groin node dissection rates in vulvar carcinoma: a population-based cohort study. Gynecol Oncol 2015;139:465470.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Salani R, Khanna N, Frimer M, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146:310.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Maggino T, Landoni F, Sartori E, et al. Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study. Cancer 2000;89:116122.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Mahner S, Prieske K, Grimm D, et al. Systemic treatment of vulvar cancer. Expert Rev Anticancer Ther 2015;15:629637.

  • 83.

    Salom EM, Penalver M. Recurrent vulvar cancer. Curr Treat Options Oncol 2002;3:143153.

  • 84.

    Piura B, Masotina A, Murdoch J, et al. Recurrent squamous cell carcinoma of the vulva: a study of 73 cases. Gynecol Oncol 1993;48:189195.

  • 85.

    Raffetto N, Tombolini V, Santarelli M, et al. Radiotherapy alone and chemoirradiation in recurrent squamous cell carcinoma of the vulva. Anticancer Res 2003;23:31053108.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Podratz KC, Symmonds RE, Taylor WF, et al. Carcinoma of the vulva: analysis of treatment and survival. Obstet Gynecol 1983;61:6374.

  • 87.

    Chiantera V, Rossi M, De Iaco P, et al. Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients. Int J Gynecol Cancer 2014;24:156164.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Stehman FB, Bundy BN, Ball H, et al. Sites of failure and times to failure in carcinoma of the vulva treated conservatively: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1996;174:11281132; discussion 1132–1133.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Hopkins MP, Reid GC, Morley GW. The surgical management of recurrent squamous cell carcinoma of the vulva. Obstet Gynecol 1990;75:10011005.

  • 90.

    Bellati F, Angioli R, Manci N, et al. Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases. Gynecol Oncol 2005;96:227231.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017;390:16541663.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Rosen VM, Guerra I, McCormack M, et al. Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer. Int J Gynecol Cancer 2017;27:12371246.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 2015;33:21292135.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Lorusso D, Petrelli F, Coinu A, et al. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol 2014;133:117123.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Santeufemia DA, Capobianco G, Re GL, et al. Cisplatin-gemcitabine as palliative chemotherapy in advanced squamous vulvar carcinoma: report of two cases. Eur J Gynaecol Oncol 2012;33:421422.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:46494655.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018;379:341351.

  • 98.

    Tewari KS, Monk BJ, Vergote I, et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 2022;386:544555.

  • 99.

    Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016;39:98106.

  • 100.

    Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012;18:65806587.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Wherry EJ. T cell exhaustion. Nat Immunol 2011;12:492499.

  • 102.

    Hecking T, Thiesler T, Schiller C, et al. Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology. Oncotarget 2017;8:9289092903.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Howitt BE, Sun HH, Roemer MG, et al. Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva. JAMA Oncol 2016;2:518522.

  • 104.

    Naing A, Meric-Bernstam F, Stephen B, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 2020;8:e000347.

  • 105.

    How JA, Jazaeri AA, Soliman PT, et al. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Sci Rep 2021;11:3667.

  • 106.

    Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2019;37:14701478.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Shapira-Frommer R, Mileshkin L, Manzyuk L, et al. Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study. Gynecol Oncol 2022;166:211218.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:13531365.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/ repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:110.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    US FDA. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Accessed November 8, 2023. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication

    • PubMed
    • Export Citation
  • 111.

    US FDA. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Accessed November 8, 2023. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors

    • PubMed
    • Export Citation
  • 112.

    Naumann RW, Hollebecque A, Meyer T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. J Clin Oncol 2019;37:28252834.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271282.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731739.

  • 115.

    Hong DS, Bauer TM, Lee JJ, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol 2019;30:325331.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020;21:531540.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Dessources K, Aviki E, Leitao MM Jr. Lower extremity lymphedema in patients with gynecologic malignancies. Int J Gynecol Cancer 2020;30:252260.

  • 118.

    Bona AF, Ferreira KR, Carvalho RBM, et al. Incidence, prevalence, and factors associated with lymphedema after treatment for cervical cancer: a systematic review. Int J Gynecol Cancer 2020;30:16971704.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline update. J Clin Oncol 2020;38:33253348.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Stahl JM, Qian JM, Tien CJ, et al. Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy. Support Care Cancer 2019;27:14251433.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Park HS, Ratner ES, Lucarelli L, et al. Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma. Brachytherapy 2015;14:464470.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J 2018;36:8594.

  • 123.

    Borella F, Preti M, Bertero L, et al. Is there a place for immune checkpoint inhibitors in vulvar neoplasms? A state of the art review. Int J Mol Sci 2020;22:190.

  • 124.

    Schepisi G, Casadei C, Toma I, et al. Immunotherapy and its development for gynecological (ovarian, endometrial and cervical) tumors: from immune checkpoint inhibitors to chimeric antigen receptor (CAR)-T cell therapy. Cancers (Basel) 2021;13:840.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Lin KY, Frawley HC, Denehy L, et al. Exercise interventions for patients with gynaecological cancer: a systematic review and meta-analysis. Physiotherapy 2016;102:309319.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 126.

    Nekhlyudov L, Mollica MA, Jacobsen PB, et al. Developing a quality of cancer survivorship care framework: implications for clinical care, research, and policy. J Natl Cancer Inst 2019;111:11201130.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 127.

    Bober SL, Reese JB, Barbera L, et al. How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer. Curr Opin Support Palliat Care 2016;10:4454. https://journals.lww.com/co-supportiveandpalliativecare/Fulltext/2016/03000/How_to_ask_and_what_to_do__a_guide_for_clinical.12.aspx

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Damast S, Jeffery DD, Son CH, et al. Literature review of vaginal stenosis and dilator use in radiation oncology. Pract Radiat Oncol 2019;9:479491.

  • 129.

    Campbell G, Thomas TH, Hand L, et al. Caring for survivors of gynecologic cancer: assessment and management of long-term and late effects. Semin Oncol Nurs 2019;35:192201.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Society of Gynecologic Oncology. Survivorship toolkit. Accessed November 8, 2023. Available at: https://www.sgo.org/resources/survivorship-toolkit/

    • PubMed
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 3572 3572 3036
PDF Downloads 2856 2856 2483
EPUB Downloads 0 0 0